NCT00237939已完成3 期
A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)
Otsuka Pharmaceutical Development & Commercialization, Inc.21 个研究点 分布在 5 个国家目标入组 1,200 人开始时间: 2002年9月最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,200
- 试验地点
- 21
- 主要终点
- Clinical Global Impression-Improvement at endpoint
研究概览
简要总结
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical DSM-IV diagnosis of schizophrenia
- •Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required
排除标准
- •Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes
- •Prisoners or subjects compulsory detained
结局指标
主要结局
Clinical Global Impression-Improvement at endpoint
次要结局
- Patients' and caregivers' medication preference
研究者
研究点 (21)
Loading locations...
相似试验
已完成
3 期
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesSchizophrenia and Schizoaffective DisorderNCT00292409Otsuka Pharmaceutical Development & Commercialization, Inc.400
已完成
3 期
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615
已完成
2 期
An Open-Label Trial of Aripiprazole in Autism Spectrum DisordersAsperger's DisorderAutismPervasive Developmental DisorderNCT00308074Cambridge Health Alliance14
已完成
4 期
Aripiprazole in Patients With Psychosis Associated With Parkinson's DiseasePsychosesParkinson's DiseaseNCT00095810Otsuka Pharmaceutical Development & Commercialization, Inc.50
已完成
3 期
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I DisorderBipolar Disorder ManiaNCT00665366Otsuka Pharmaceutical Development & Commercialization, Inc.493